中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.024 seconds)

    PD-1 PEPTIDE INHIBITORS
    4.
    发明申请
    PD-1 PEPTIDE INHIBITORS 审中-公开
    PD-1肽抑制剂

    公开(公告)号：WO2018053218A1

    公开(公告)日：2018-03-22

    申请号：PCT/US2017/051697

    申请日：2017-09-15

    Applicant: LEIDOS, INC.

    Inventor： GUTIERREZ, Gabriel M. ,  VINAYAKA, Kotraiah ,  PANNUCCI, James ,  AYALA, Ramses

    IPC: A61K38/10 ,  C07K7/08 ,  A61P35/00 ,  A61P31/00

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

    Abstract translation: 本公开提供了对检查点受体“程序性死亡1”具有强亲和力的肽。 （PD-1）。 这些肽阻断PD-1与其配体PDL1的相互作用，因此可以用于各种治疗目的，例如抑制包括癌症在内的过度增殖性病症的进展，治疗感染性疾病，增强对疫苗接种的反应和治疗败血症。

    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION
    5.
    发明申请
    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION 审中-公开

    公开(公告)号：WO2022169895A1

    公开(公告)日：2022-08-11

    申请号：PCT/US2022/014970

    申请日：2022-02-02

    Applicant: GEOVAX, INC. ,  LEIDOS, INC.

    Inventor： HAUSER, Mary Jo ,  DOMI, Arban ,  GUTIERREZ, Gabriel ,  PANNUCCI, James ,  KOTRAIAH, Vinayaka ,  PHARES, Timothy ,  BUONTEMPO, Peter ,  BROWNE, Cecille

    IPC: A61K35/768 ,  C12N15/86 ,  C12N15/87 ,  C12N15/90

    Abstract: The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof. When used in concert with the administration of an antigen during a vaccination strategy, the immune checkpoint expressing MV A viral construct provides significantly improved antigen-specific CD8+ T cell expansion, increased antigenic responses, and improved vaccination efficacy.

    LAG3 BINDING PEPTIDES
    6.
    发明申请
    LAG3 BINDING PEPTIDES 审中-公开

    公开(公告)号：WO2020237050A1

    公开(公告)日：2020-11-26

    申请号：PCT/US2020/033996

    申请日：2020-05-21

    Applicant: LEIDOS, INC.

    Inventor： GUTIERREZ, Gabriel M. ,  KOTRAIAH, Vinayaka ,  PHARES, Timothy W. ,  PANNUCCI, James ,  MANSOUR, Marc

    IPC: A61P35/00 ,  C07K7/00 ,  A61P25/28

    Abstract: This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES
    7.
    发明申请
    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES 审中-公开

    公开(公告)号：WO2018218137A1

    公开(公告)日：2018-11-29

    申请号：PCT/US2018/034625

    申请日：2018-05-25

    Applicant: LEIDOS, INC.

    Inventor： GUTIERREZ, Gabriel M. ,  KOTRAIAH, Vinayaka ,  PHARES, Timothy ,  PANNUCCI, James

    IPC: C07K14/705 ,  A61K38/17

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

Patent Agency Ranking